AU2010289871B2 - Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes - Google Patents

Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Download PDF

Info

Publication number
AU2010289871B2
AU2010289871B2 AU2010289871A AU2010289871A AU2010289871B2 AU 2010289871 B2 AU2010289871 B2 AU 2010289871B2 AU 2010289871 A AU2010289871 A AU 2010289871A AU 2010289871 A AU2010289871 A AU 2010289871A AU 2010289871 B2 AU2010289871 B2 AU 2010289871B2
Authority
AU
Australia
Prior art keywords
alkyl
group
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010289871A
Other languages
English (en)
Other versions
AU2010289871A1 (en
Inventor
Tesfaye Biftu
Ping Chen
Danqing Feng
Xiaoxia Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2010289871A1 publication Critical patent/AU2010289871A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK SHARP & DOHME CORP.
Application granted granted Critical
Publication of AU2010289871B2 publication Critical patent/AU2010289871B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010289871A 2009-09-02 2010-08-23 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Ceased AU2010289871B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23924209P 2009-09-02 2009-09-02
US61/239,242 2009-09-02
US26227809P 2009-11-18 2009-11-18
US61/262,278 2009-11-18
PCT/US2010/046270 WO2011028455A1 (en) 2009-09-02 2010-08-23 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Publications (2)

Publication Number Publication Date
AU2010289871A1 AU2010289871A1 (en) 2012-04-26
AU2010289871B2 true AU2010289871B2 (en) 2014-07-10

Family

ID=43649576

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010289871A Ceased AU2010289871B2 (en) 2009-09-02 2010-08-23 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Country Status (12)

Country Link
US (1) US8455533B2 (enEXAMPLES)
EP (1) EP2473047B1 (enEXAMPLES)
JP (1) JP5734981B2 (enEXAMPLES)
KR (1) KR20120092096A (enEXAMPLES)
CN (1) CN102595897A (enEXAMPLES)
AU (1) AU2010289871B2 (enEXAMPLES)
BR (1) BR112012004335A8 (enEXAMPLES)
CA (1) CA2771352A1 (enEXAMPLES)
IN (1) IN2012DN00721A (enEXAMPLES)
MX (1) MX2012002633A (enEXAMPLES)
RU (1) RU2550508C2 (enEXAMPLES)
WO (1) WO2011028455A1 (enEXAMPLES)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8691832B2 (en) 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
CN105001219A (zh) 2011-02-25 2015-10-28 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
KR20140034861A (ko) 2011-06-29 2014-03-20 머크 샤프 앤드 돔 코포레이션 디펩티딜 펩티다제-iv 억제제의 신규한 결정질 형태
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9156848B2 (en) 2012-07-23 2015-10-13 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
TWI500613B (zh) * 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
MY181641A (en) 2014-06-17 2020-12-30 Sichuan Haisco Pharmaceutical Co Ltd Amino pyran ring derivative and composition and use thereof
WO2016014324A1 (en) 2014-07-21 2016-01-28 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-iv inhibitors
CN105985357A (zh) * 2015-02-12 2016-10-05 北京赛林泰医药技术有限公司 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂
TWI681962B (zh) * 2015-08-26 2020-01-11 大陸商四川海思科製藥有限公司 胺基六員環類衍生物及其在醫藥上的應用
WO2018222598A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
CN107459501B (zh) * 2017-08-22 2020-06-09 钟桂发 一种奥格列汀的手性中间体的制备方法
KR102736360B1 (ko) 2017-12-22 2024-11-28 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
MY208423A (en) * 2018-02-06 2025-05-08 Sichuan Haisco Pharmaceutical Co Ltd Composition of aminopyran derivative
CN111954525B (zh) 2018-04-02 2023-12-26 凯莫森特里克斯股份有限公司 稠合双环C5aR拮抗剂的前药
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070232676A1 (en) * 2006-03-28 2007-10-04 Tesfaye Biftu Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
JP2001515482A (ja) 1997-03-07 2001-09-18 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規なベンズイミダゾールインヒビター
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
MY132924A (en) 1998-05-04 2007-10-31 Point Therapeutics Inc Hematopoietic stimulation
PT1112275E (pt) 1998-09-09 2003-12-31 Metabasis Therapeutics Inc Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
CZ20013767A3 (cs) 1999-05-17 2002-04-17 Novo Nordisk A/S Sloučenina, farmaceutický prostředek, pouľití sloučeniny a způsob léčení
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
DK1328271T3 (da) 2000-10-27 2008-10-13 Probiodrug Ag Behandling af neurologiske og neurofysiologiske sygdomme
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
PL375302A1 (en) 2002-08-29 2005-11-28 Merck & Co, Inc. Indoles having anti-diabetic activity
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004066963A2 (en) 2003-01-17 2004-08-12 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2005265148B2 (en) 2004-06-21 2011-01-20 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20090292110A1 (en) 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
US7718667B2 (en) 2004-09-28 2010-05-18 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CN101031300A (zh) 2004-10-01 2007-09-05 默克公司 用于治疗或预防糖尿病的作为二肽基肽酶－ⅳ抑制剂的氨基哌啶化合物
KR20070068407A (ko) 2004-10-25 2007-06-29 노파르티스 아게 Ｄｐｐ―ｉｖ 억제제, ｐｐａｒ 항당뇨병제 및메트포르민의 조합물
JP4999698B2 (ja) 2004-11-29 2012-08-15 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防用のジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合アミノピペリジン
AU2006283062B2 (en) 2005-08-26 2011-04-14 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1831165A1 (en) 2004-12-20 2007-09-12 F. Hoffmann-Roche AG 4-aminopiperidine derivatives
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
AU2006251660B2 (en) 2005-05-25 2011-05-26 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
BRPI0612069A2 (pt) 2005-06-13 2009-01-20 Imp Innovations Ltd compostos e seus efeitos sobre o comportamento de alimentaÇço
WO2007070434A2 (en) 2005-12-14 2007-06-21 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
AU2007208405B2 (en) 2006-01-25 2011-05-26 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP5161795B2 (ja) * 2006-02-15 2013-03-13 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしてのアミノテトラヒドロピラン
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
CA2647027A1 (en) 2006-03-20 2007-09-27 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
CN101410400B (zh) * 2006-03-28 2012-09-05 默沙东公司 作为用于糖尿病治疗或者预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
AU2007254357B2 (en) * 2006-05-16 2011-07-21 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP2010500868A (ja) 2006-07-18 2010-01-14 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
JP5232160B2 (ja) 2006-11-14 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
CA2691010A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
US20100184758A1 (en) 2007-07-19 2010-07-22 Dobbelaar Peter H Beta carboline derivatives as antidiabetic compounds
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
CA2696211C (en) 2007-08-21 2015-05-26 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
CN102272135A (zh) 2008-10-08 2011-12-07 百时美施贵宝公司 唑并吡咯酮黑色素浓集激素受体-1拮抗剂
JO2870B1 (en) * 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2480082A4 (en) 2009-09-25 2014-01-15 Merck Sharp & Dohme SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070232676A1 (en) * 2006-03-28 2007-10-04 Tesfaye Biftu Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Also Published As

Publication number Publication date
EP2473047A4 (en) 2013-02-13
CA2771352A1 (en) 2011-03-10
EP2473047B1 (en) 2014-08-13
BR112012004335A8 (pt) 2016-06-21
WO2011028455A1 (en) 2011-03-10
RU2012112471A (ru) 2013-10-10
MX2012002633A (es) 2012-04-20
JP2013503864A (ja) 2013-02-04
CN102595897A (zh) 2012-07-18
US20120149734A1 (en) 2012-06-14
AU2010289871A1 (en) 2012-04-26
RU2550508C2 (ru) 2015-05-10
EP2473047A1 (en) 2012-07-11
IN2012DN00721A (enEXAMPLES) 2015-06-19
JP5734981B2 (ja) 2015-06-17
BR112012004335A2 (pt) 2015-09-08
KR20120092096A (ko) 2012-08-20
US8455533B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
AU2010289871B2 (en) Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2009314191B2 (en) Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US8853212B2 (en) Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
US8716482B2 (en) Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
HK1187343A (en) Combination drugs comprising aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
HK1187344A (en) Combination drugs comprising aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
HK1154849B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired